

POSTER PRESENTATION

Open Access

Development of anti-GPC-1 (glypican-1)-CAR-T cells for adoptive T cell immunotherapies for squamous cell carcinoma

Tomonori Yaguchi^{1*}, Kenji Morii¹, Satoshi Serada², Tetsuji Naka², Yutaka Kawakami¹

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Immunotherapies using T cells transduced with a chimeric antigen receptor (CAR) gene have been demonstrated as a promising strategy for cancer treatment. CAR-T cells can specifically recognize tumor antigen expressed on the cell surface and eliminate tumors. Although CAR-T cell therapies for hematological malignancies targeting CD19 have recently showed promising clinical outcomes, few success cases have been reported for solid tumors because of the lack of specific cell surface antigens. Glypican-1 (GPC-1) is the member of the glypican family of heparin sulfate proteoglycans that are attached to the cell surface by a glycosylphosphatidylinositol (GPI) anchor. We have previously found GPC-1 were preferentially expressed in squamous cell carcinoma including esophageal cancers, lung cancers, and cervical cancers, and played an important role in cancer growth. We have developed monoclonal antibodies against GPC-1 having *in vivo* anti-tumor effects. In this study, we have developed anti-GPC-1-CAR-T cells and explored their potential for squamous cell carcinoma treatment. The retroviral expression vectors containing the CAR gene consisting of variable regions of the anti-GPC-1 mAb, and CD3 ζ /CD28 intracellular signaling domains were generated, and we transduced it into human peripheral blood T cells. The generated anti-GPC-1 CAR-T cells were activated and propagated by IL2 and anti-CD3 Ab. Purified CD8⁺ anti-GPC-1 CAR-T cells specifically recognized GPC-1 expressed on cancer cells, produced high amount of IFN- γ and TNF- α , and showed high cytotoxic activities. Purified CD4⁺ anti-GPC-1 CAR-T cells also showed the production of Th1 and Th2 cytokines and cytotoxic activities in a

GPC-1-specific manner. These results indicate that GPC1-targeted CAR-T cells have a strong ability to eliminate cancer cells and may be an attractive strategy for treatment of patients with squamous cell carcinoma.

Authors' details

¹Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine., Tokyo, Japan. ²Laboratory of Immune Signal, National Institute of Biomedical Innovation, Osaka, Japan.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P125

Cite this article as: Yaguchi et al.: Development of anti-GPC-1 (glypican-1)-CAR-T cells for adoptive T cell immunotherapies for squamous cell carcinoma. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P125.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine., Tokyo, Japan
Full list of author information is available at the end of the article